Acute Liver Failure (ALF)


 I. AASLD definition Definition

Acute Liver Failure (ALF) is defined as the rapid deterioration of liver function in a patient without pre-existing liver disease, characterized by:

  • Hepatic encephalopathy, and
  • Coagulopathy (INR ≥1.5),
  • Within 26 weeks of the onset of symptoms.


 II. Etiology

🔸 A. Drug-induced (most common in Western countries)

Agent

Notes

Paracetamol (acetaminophen)

Most common cause; dose >10–15 g

Anti-TB drugs (INH, rifampin, pyrazinamide)

Especially in reactivation

Halothane

Idiosyncratic hepatotoxicity

Valproate, amiodarone, phenytoin

Mitochondrial toxicity


🔸 B. Viral hepatitis (common in developing countries)

  • Hepatitis A, B, E (especially in pregnancy)
  • Herpes simplex, CMV, EBV

🔸 C. Other Causes

Category

Examples

Ischemia

Shock liver, Budd–Chiari

Autoimmune

Autoimmune hepatitis

Infiltrative

Lymphoma, leukemia

Wilson’s disease

Especially in young adults

Toxins

Amanita phalloides, aflatoxins



 III. Classification

Type

Definition

Hyperacute

Encephalopathy within 7 days (e.g., paracetamol)

Acute

8–28 days

Subacute

5–12 weeks


  • Hyperacute ALF: Higher ICP, better transplant-free survival
  • Subacute ALF: Lower ICP, poorer outcomes


 IV. Pathophysiology

🔸 1. Massive hepatocellular necrosis synthetic and detoxifying capacity

🔸 2. Hyperbilirubinemia, coagulopathy, hypoglycemia, lactic acidosis

🔸 3. Ammonia accumulation cerebral edema

🔸 4. SIRS and immune dysregulation sepsis-like syndrome

🔸 5. Multiorgan failure in late stages


 V. Clinical Features

System

Manifestation

Neurologic

Encephalopathy, cerebral edema, seizures, ICP

Hematologic

INR, platelets, DIC

Renal

AKI, HRS

GI/hepatic

Jaundice, ascites, hypoglycemia

Cardiovascular

Hypotension, high-output shock

Pulmonary

ARDS, hepatopulmonary syndrome

Infectious

High sepsis risk despite immunocompetence



 VI. Diagnosis

🔸 1. Liver function tests (LFTs)

  • AST, ALT: Very high (>1000 IU/L) in ischemia, paracetamol
  • Bilirubin: Elevated (total/direct)

🔸 2. Coagulation profile

  • INR ≥ 1.5 (diagnostic criteria)
  • PT: prolonged

🔸 3. Ammonia levels

  • Correlate with risk of encephalopathy/cerebral edema

🔸 4. Viral serology (HAV, HBV, HCV, HEV, HSV, CMV)

🔸 5. Autoimmune markers

  • ANA, SMA, LKM-1

🔸 6. Ceruloplasmin, 24-hr urinary copper: to rule out Wilson’s

🔸 7. Toxicology screen

  • Paracetamol, salicylates, alcohol

🔸 8. Imaging

  • CT/MRI: rule out ICH or space-occupying lesions (if encephalopathy)


 VII. Prognostic Scoring

🔸 1. King’s College Criteria

For Paracetamol-induced ALF:

  • pH < 7.3 after resuscitation
    OR
  • PT > 100 sec (INR >6.5), creatinine > 3.4 mg/dL, Grade III–IV HE

For Non-paracetamol ALF:

  • PT > 100 sec (INR >6.5)
    OR
  • Any 3 of:
    • Age <10 or >40
    • Jaundice to encephalopathy >7 days
    • INR >3.5
    • Bilirubin >17.6
    • Drug-induced or non-A/non-B hepatitis

🔸 2. Model for End-Stage Liver Disease (MELD)


 VIII. Management

 Requires ICU admission in most cases

🔸 A. Airway and CNS management

Target

Measures

Grade III/IV HE

Elective intubation

ICP risk

Elevate HOB 30°, avoid hypoxia/hypercarbia

Sedation

Propofol preferred (short-acting, anticonvulsant)

Mannitol

For cerebral edema (0.25–1 g/kg)

Hypertonic saline

Maintain Na 145–150

Avoid

Hypotension, hyperthermia

Avoid steroids (not useful)

  • ICP monitoring controversial (bleeding risk)



🔸 B. Hemodynamic Support

  • Avoid overzealous fluid resuscitation
  • Norepinephrine for vasopressor support
  • Albumin in fluid resuscitation (oncotic support)


🔸 C. Renal Support

  • Prevent and treat Hepatorenal Syndrome
  • CRRT preferred in hemodynamically unstable


🔸 D. Coagulation

  • INR correction only if bleeding or invasive procedure
  • Platelets > 50,000/µL before invasive procedures
  • FFP, cryoprecipitate (fibrinogen >100 mg/dL)
  • Vitamin K


🔸 E. Infection Control

ALF = immunocompromised state.

Up to 80% develop infection.

Common:

  • Pneumonia
  • UTI
  • Line sepsis

Strategy:

  • Low threshold for cultures
  • Daily surveillance
  • Empiric broad-spectrum antibiotics if unstable
  • Antifungal if prolonged ICU stay

Infection worsens encephalopathy.

 Should We Give Prophylactic Antibiotics?

Controversial.

Current Approach:

  • NOT routinely recommended for all stable ALF patients
  • BUT low threshold to start empiric antibiotics if:
    • Grade III/IV encephalopathy
    • On ventilator
    • On vasopressors
    • Awaiting transplant

Common empiric choices:

  • Piperacillin-tazobactam
  • Meropenem (if high risk)

Antifungal:

  • Consider if ICU >5 days or high risk

🔸 F. Glucose Management

  • Avoid hypoglycemia: 10% dextrose infusion

🔸 G. Nutritional Support

Goals

  • Prevent catabolism
  • Reduce ammonia production
  • Maintain gut integrity


Energy Requirement

25–30 kcal/kg/day


Protein

OLD CONCEPT : Restrict protein
NEW GUIDELINE :

  • 1.2–1.5 g/kg/day
  • Avoid prolonged protein restriction
  • Vegetable protein preferred
  • BCAA may help in encephalopathy


Route

Enteral preferred
Start within 24 hours if stable

Avoid prolonged fasting worsens muscle breakdown ammonia


Glucose

  • Continuous dextrose infusion
  • Hourly monitoring
  • Hypoglycemia common due to glycogen depletion

N-ACETYLCYSTEINE (NAC)

In Paracetamol toxicity

Mechanism:

  • Replenishes glutathione
  • Enhances NAPQI detoxification
  • Improves microcirculation


 Extended Infusion Strategy (ICU Practice)

Continue NAC if:

  • ALT rising
  • INR worsening
  • Detectable paracetamol level
  • Ongoing liver failure


NON-Paracetamol ALF

Evidence supports:

  • Improved transplant-free survival
  • Better oxygen delivery
  • Reduced oxidative stress

👉 Current guidelines: Start NAC in all ALF unless contraindicated



 AMMONIA CONTROL

Ammonia is central in cerebral edema.

Strategies:

  • Lactulose (if not intubated)
  • Rifaximin
  • CRRT (effective removal)
  • Avoid constipation

Ammonia >150–200 µmol/L high cerebral edema risk


IX. Liver Transplantation

Indications:

  • Fulfillment of King’s College Criteria
  • Persistent encephalopathy or coagulopathy
  • Rising bilirubin/INR despite supportive care

 Only definitive treatment in many cases